Field Evaluation of Two Rapid Diagnostic Tests for Neisseria meningitidis Serogroup A during the 2006 Outbreak in Niger
Open Access
- 5 October 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (10) , e7326
- https://doi.org/10.1371/journal.pone.0007326
Abstract
The Pastorex® (BioRad) rapid agglutination test is one of the main rapid diagnostic tests (RDTs) for meningococcal disease currently in use in the “meningitis belt”. Earlier evaluations, performed after heating and centrifugation of cerebrospinal fluid (CSF) samples, under good laboratory conditions, showed high sensitivity and specificity. However, during an epidemic, the test may be used without prior sample preparation. Recently a new, easy-to-use dipstick RDT for meningococcal disease detection on CSF was developed by the Centre de Recherche Médicale et Sanitaire in Niger and the Pasteur Institute in France. We estimate diagnostic accuracy in the field during the 2006 outbreak of Neisseria meningitidis serogroup A in Maradi, Niger, for the dipstick RDT and Pastorex® on unprepared CSF, (a) by comparing each test's sensitivity and specificity with previously reported values; and (b) by comparing results for each test on paired samples, using McNemar's test. We also (c) estimate diagnostic accuracy of the dipstick RDT on diluted whole blood. We tested unprepared CSF and diluted whole blood from 126 patients with suspected meningococcal disease presenting at four health posts. (a) Pastorex® sensitivity (69%; 95%CI 57–79) was significantly lower than found previously for prepared CSF samples [87% (81–91); or 88% (85–91)], as was specificity [81% (95%CI 68–91) vs 93% (90–95); or 93% (87–96)]. Sensitivity of the dipstick RDT [89% (95%CI 80–95)] was similar to previously reported values for ideal laboratory conditions [89% (84–93) and 94% (90–96)]. Specificity, at 62% (95%CI 48–75), was significantly lower than found previously [94% (92–96) and 97% (94–99)]. (b) McNemar's test for the dipstick RDT vs Pastorex® was statistically significant (p® without prior CSF preparation were poorer than previously reported results from prepared samples; therefore we caution against using this test during an epidemic if sample preparation is not possible. For the dipstick RDT, sensitivity was similar to, while specificity was not as high as previously reported during a more stable context. Further studies are needed to evaluate its field performance, especially for different populations and other serogroups.Keywords
This publication has 10 references indexed in Scilit:
- Biological diagnosis of meningococcal meningitis in the African meningitis belt: Current epidemic strategy and new perspectivesVaccine, 2007
- Meningitis Serogroup W135 Outbreak, Burkina Faso, 2002Emerging Infectious Diseases, 2007
- Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in NigerClinical Infectious Diseases, 2007
- High sensitivity and specificity of the Pastorex® latex agglutination test for Neisseria meningitidis serogroup A during a clinical trial in NigerTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- New Rapid Diagnostic Tests for Neisseria meningitidis Serogroups A, W135, C, and YPLoS Medicine, 2006
- Scaling up of PCR-based surveillance of bacterial meningitis in the African meningitis belt: indisputable benefits of multiplex PCR assay in NigerTransactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Evaluation of the Pastorex® meningitis kit for the rapid identification of Neisseria meningitidis serogroups A and W135Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006
- Polymerase Chain Reaction Assay and Bacterial Meningitis Surveillance in Remote Areas, NigerEmerging Infectious Diseases, 2003
- Interval estimation for the difference between independent proportions: comparison of eleven methodsStatistics in Medicine, 1998
- Polymerase Chain Reaction for Case Ascertainment of Meningococcal Meningitis: Application to the Cerebrospinal Fluids Collected in the Course of the Norwegian Meningococcal Serogroup B Protection TrialScandinavian Journal of Infectious Diseases, 1996